Asimov launched its AAV Edge Stable Producer system with the goal of addressing the shortcomings of traditional transient transfection-based production and bringing AAV manufacturing standards closer ...

IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month ...

New expedited service line designed for biotechs with timeline constraints, launched in response to client demandCan accelerate timeline to GMP ...

Asimov, the synthetic biology company advancing the design and production of therapeutics, today announced the launch of the AAV Edge System, a comprehensive suite of tools for adeno-associated viral ...

Adeno-associated viruses (AAVs) have emerged as essential tools for delivering genetic material into tissues and engineering therapeutic cells. As gene and cell therapies advance, researchers optimize ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

Targeting T cells with ustekinumab is a potential therapeutic strategy for AAV-GN that merits additional evaluation in clinical trials. To further clarify and define the role of specific T-cell ...

The first peer-reviewed journal in the field of human gene therapy, providing all-inclusive coverage of the research, methods, and clinical developments that are driving today's explosion of gene ...

For the millions of people living with genetic diseases like muscular dystrophy and inherited liver disorders, one of the ...